Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke

Starting soon

Conditions studied: Acute Ischemic Stroke, Tenecteplase

In brief

The benefit of intravenous tenecteplase in very old patients with acute ischemic stroke (AIS) remain uncertain. This real-world study aims to evaluate the effectiveness and safety of intravenous tenecteplase in AIS patients aged 80 years or older within 4.5 hours of symptom onset.

Key facts

Study ID

NCT07475936

Run by

First Affiliated Hospital of Guangxi Medical University

People needed

392

Starts

2026-04-01

Expected to finish

2027-12-01

Last updated by the study team

2026-03-17

Who can join

Age: 80 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 80 years;
• Clinically diagnosed with acute ischemic stroke and arrived at the hospital within 4.5 hours of symptom onset;
• Informed consent signed by the patient or legally authorized representative.

You may not qualify if…

• Any contraindication to intravenous thrombolysis (excluding age);
• Previous treatment with other thrombolytic agents such as alteplase, urokinase, plasminogen activator, or reteplase;
• Current participation in other interventional studies;
• The investigator deems the patient unsuitable for this study or the study might pose significant risk to the patient (e.g., due to psychiatric disorders, cognitive or emotional impairments that prevent understanding or adherence to study procedures and/or follow-up).

Where it is running

• The First Affiliated Hospital of Guangxi Medical University — Nanning, Guangxi, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.